Asahi Kasei Pharma logo

Asahi Kasei Pharma

Asia, Tokyo, Japan, Tokyo

Description

Asahi Kasei Pharma is a specialty pharmaceutical firm with a global presence by focusing on the development of new world-class drugs.

Investor Profile

Asahi Kasei Pharma has made 5 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series C (40%)
  • Series A (40%)
  • Series B (20%)

Country Focus

  • Japan (60%)
  • United Kingdom (40%)

Industry Focus

  • Biotechnology
  • Medical
  • Health Care
  • Health Diagnostics
  • Medical Device
  • Analytics
  • Nursing And Residential Care
  • Pharmaceutical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Asahi Kasei Pharma frequently co-invest with?

Johnson & Johnson Innovation – JJDC
North America, Massachusetts, United States, Cambridge
Co-Investments: 2
SV Health Investors
North America, Massachusetts, United States, Boston
Co-Investments: 2
Ono Venture Investment
North America, California, United States, San Francisco
Co-Investments: 2
Longwood Fund
North America, Massachusetts, United States, Boston
Co-Investments: 2
Beyond Next Ventures
Asia, Tokyo, Japan, Tokyo
Co-Investments: 2
SR One
North America, Massachusetts, United States, Cambridge
Co-Investments: 2
Jeito Capital
Europe, Ile-de-France, France, Paris
Co-Investments: 2
F-Prime Capital
North America, Massachusetts, United States, Cambridge
Co-Investments: 2
IP Group
Europe, England, United Kingdom, London
Co-Investments: 2
Adjuvant Capital
North America, New York, United States, New York
Co-Investments: 2

What are some of recent deals done by Asahi Kasei Pharma?

Curreio

Shinjuku, Yamanashi, Japan

Curreio is a biotechnology platform that provides contract business for structural analysis using cryo-electron microscopy.

AnalyticsBiotechnologyMedicalNursing and Residential Care
Series AMar 20, 2023
Pulmocide

London, England, United Kingdom

Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.

BiotechnologyHealth CareHealth DiagnosticsMedicalMedical Device
Series CDec 6, 2022
Amount Raised: $52,000,000
LUCA Science

Tokyo, Tokyo, Japan

LUCA Science develops innovative treatments intended for mitochondrial and related diseases.

BiotechnologyHealth CarePharmaceutical
Series BJun 6, 2022
Amount Raised: $29,203,600
Curreio

Shinjuku, Yamanashi, Japan

Curreio is a biotechnology platform that provides contract business for structural analysis using cryo-electron microscopy.

AnalyticsBiotechnologyMedicalNursing and Residential Care
Series AJun 23, 2021
Pulmocide

London, England, United Kingdom

Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.

BiotechnologyHealth CareHealth DiagnosticsMedicalMedical Device
Series CMay 27, 2021
Amount Raised: $92,000,000